Patent covers brilaroxazine use for treating Pulmonary Fibrosis-Similar patents have also been granted in key markets around the world ...

An announcement from Vicore Pharma Holding AB ( ($SE:VICO) ) is now available. Vicore Pharma Holding AB announced a directed share issue to raise ...

An update from Vicore Pharma Holding AB ( ($SE:VICO) ) is now available. Vicore Pharma Holding AB has successfully raised approximately USD 48 ...

Angiotensin-converting enzyme (ACE) inhibitor therapy may reduce all-cause mortality in idiopathic pulmonary fibrosis (IPF) but not in COPD.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Treatment with Endeavor Biomedicines’ experimental oral therapy ENV-101 (taladegib) improved lung function in people with IPF ...

Melbourne-based RAGE Biotech has raised $29 million in Series A to take its treatment for chronic lung disease into ...

Each year, the European Lung Foundation (ELF) recognises outstanding research that advances patient-centred care and promotes ...

The investigators also reported that LTI-03 helped preserve alveolar epithelial type II (AT2) progenitor cells, which are essential for lung repair and regeneration. Current IPF therapies primarily ...

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

Insilico Medicine to showcase generative AI platform and introduce their latest AI-driven Pulmonary Fibrosis clinical research at PFF Summit 2025 in Chicago, IL ...

AI transforms healthcare by enhancing disease detection, patient care and hospital efficiency but requires careful implementation to ensure equity and effectiveness. Managed Healthcare Executive ...